Significance of chemokines and activated platelets in patients with diabetes

Nomura, Shosaku; Shouzu, Akira; Omoto, Seitaro; Nishikawa, Mitsushige; Fukuhara, Shirou

doi:10.1046/j.1365-2249.2000.01324.x

Cited by 159 publications

(112 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data from several studies linked MCP-1 and IL-8 to type 2 diabetes, but in particular data on IL-8 were based on rather small casecontrol studies [14,16]. Increased MCP-1 concentrations in type 2 diabetes patients were reported in a small Japanese case-control study [15], in elderly women selected from a population survey in Italy [17], in patients with prevalent cardiovascular disease [18,20] and in the population-based Dallas Heart Study [19]. Since the association of elevated MCP-1 levels and prevalent type 2 diabetes was not seen in the Dallas Heart Study when all individuals with subclinical atherosclerosis were excluded and was also absent in the cross-sectional KORA Survey 2000 [32], it remained unclear whether there was a link between MCP-1 and type 2 diabetes and how this relationship might be modulated by the concomitant presence of cardiovascular disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002

et al. 2006

View full text Add to dashboard Cite

Aims/hypothesis: The chemokines monocyte chemoattractant protein-1 (MCP-1), IL-8 and interferon-γ-inducible protein-10 (IP-10) are released by adipocytes and appear to be involved in atherosclerosis. We hypothesised that these chemokines may be risk factors for the development of type 2 diabetes. Subjects and methods: Using a case-cohort design based on data from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)/Kooperative Gesundheitsforschung in der Region Augsburg/Cooperative Health Research in the Region of Augsburg (KORA Augsburg) study, chemokine levels at baseline were analysed in 526 individuals with and 1,695 individuals without incident type 2 diabetes. The mean follow-up time was 10.8 years. Results: MCP-1 was associated with type 2 diabetes, largely independently of classic risk factors, whereas various clinical and metabolic parameters as well as lifestyle factors were major confounders of the association of IL-8 and IP-10 with type 2 diabetes. Further adjustment for C-reactive protein (CRP) and IL-6 had no impact on the observed associations. The hazard ratio (HR) for subjects with systemic concentrations of all three chemokines (MCP-1, IL-8 and IP-10) above the respective median compared with those with all chemokines below or equal to the median was 1.79 (95% CI 1.18-2.72) and was comparable with the HR for elevated CRP and IL-6 together (adjusted for age, sex, survey, BMI, systolic blood pressure, total cholesterol:HDL cholesterol ratio, physical activity, alcohol intake, smoking and parental history of diabetes). Conclusions/interpretation: Elevated concentrations of MCP-1, IL-8 and IP-10 are associated with incident type 2 diabetes. Whereas the association of IL-8 and IP-10 with diabetes was attenuated by multivariable adjustment, high MCP-1 levels contributed to diabetes risk independently of previously described clinical, metabolic and immunological risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It has been postulated that chemokine expression might be an important step in the recruitment and activation of peripheral blood leucocytes in atherosclerotic lesions [12] and adipose tissue [13]. In particular elevated levels of MCP-1 and IL-8 may be associated with type 2 diabetes [14][15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Etiology of HPR is complex, and seems to be a result of hyperglycemia, metabolic disorders, oxidative stress and inflammation [3]. In particular, T2DM patients have higher concentrations of inflammatory markers, platelet activation and coagulation markers than healthy subjects [4][5][6]. Moreover, higher concentrations of inflammatory markers correlate with increased CV risk [7,8].…”

Section: Introductionmentioning

confidence: 99%

Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study

Rosiak

Postuła²,

Kapłon‐Cieślicka³

et al. 2013

Cardiol J

View full text Add to dashboard Cite

show abstract

“…18,19 Recently, we reported a correlation between levels of P-selectin-positive platelets and chemokines. 20 In addition to the hypercoagulability resulting from monocyte and endothelial cell activation, diabetic patients also show platelet hyperaggregability with increased levels of platelet activation-markers such as P-selectin. 21 Dihydropyridine Ca channel blockers were recently reported to protect the endothelial function of renal resistance arteries in hypertensive rats 22 and mesenteric arteries in circulatory shock rats.…”

Section: Introductionmentioning

confidence: 99%

Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus

et al. 2005

Self Cite

View full text Add to dashboard Cite

We investigated the effects of long-term benidipine treatment on levels of monocyte and endothelial cell activation markers in hypertensive patients with (n ¼ 28) and without (n ¼ 10) type 2 diabetes mellitus. Benidipine, 4 mg/day, was administered for 6 months; there were no other changes in any of the patients pharmacologic regimens during benidipine treatment. Clinical and biochemical data obtained before and after benidipine administration were compared; all markers were measured by ELISA. The levels of platelet activation markers (CD62P, CD63, and PAC-1), microparticles (monocytederived microparticles: MDMPs, and endothelial cellderived microparticles: EDMPs), chemokines (monocyte chemotactic peptide 1: MCP-1, regulated on activation normally T-cell expressed and secreted: RANTES) and soluble adhesion markers (soluble E-selectin and soluble ICAM-1) differed in the control and hypertension groups. In addition, levels of platelet, monocyte, and endothelial cell activation markers, microparticles, chemokines, and soluble adhesion molecules were higher in hypertensive patients than in those without type 2 diabetes. Furthermore, benidipine administration decreased the concentrations of all these markers. The effect of this drug was significant in diabetes patients with high levels of antioxidized low-density lipoprotein (LDL) antibody. These results suggest that benidipine is effective for the treatment of oxLDL-dependent vascular disorders in hypertensive patients with type 2 diabetes.

show abstract

Significance of chemokines and activated platelets in patients with diabetes

Cited by 159 publications

References 53 publications

Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002

Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002

Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study

Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus

Contact Info

Product

Resources

About